Company Overview
BillionToOne Inc. (NASDAQ: BLLN) is a molecular diagnostics company headquartered in Menlo Park, California. The firm develops next‑generation diagnostic tests based on its patented Quantitative Counting Templates™ (QCT™) technology, which claims to enable accurate counting of DNA molecules at the single‑molecule level. The company is listed on the Nasdaq exchange and trades in USD.
| Item | Detail |
|---|---|
| Sector | Health Care |
| Market Capitalization | $4,370,000,000 |
| 52‑Week High (2026‑08‑04) | $150.44 |
| 52‑Week Low (2026‑03‑11) | $61.96 |
| Closing Price (2026‑11‑18) | $90.20 |
| Price‑Earnings Ratio | 125.31 |
Recent Events (2026‑11‑18)
1. Short‑Sale Allegations and Company Response
At 21:34 UTC, a report on de.investing.com indicated that BillionToOne had issued a formal statement refuting allegations presented in a short‑seller research report. The company denied the claims made by the short seller, asserting that the analysis was inaccurate and potentially misleading. No further details were disclosed beyond the rebuttal.
2. Share Price Decline Following Short Report
Earlier on the same day, seekingalpha.com reported a decline in BillionToOne’s share price after the publication of a short‑sale research note by Fuzzy Panda Research. The report was linked to a negative outlook on the company’s business prospects, and the market reaction manifested in a downward movement in the stock’s trading price.
3. Participation in Piper Sandler Healthcare Conference
On 13:05 UTC, globenewswire.com announced that BillionToOne’s management would participate in the Piper Sandler 38th Annual Healthcare Conference on Tuesday, December 1, 2026. The company will host a fireside chat from 3:00 pm to 3:25 pm Eastern Time. A live webcast and an archived recording will be available through the firm’s investor relations website. This event is positioned as an opportunity for the company to discuss its strategic direction and technological innovations with industry stakeholders.
Market Impact
The combined effect of the short‑sale allegations and the negative research note contributed to a noticeable decline in the company’s market value on 2026‑11‑18. While the firm’s management has publicly contested the negative assertions, the short‑seller activity remains a point of concern for investors. The upcoming conference engagement may serve as a platform to address investor questions and reinforce confidence in BillionToOne’s product pipeline and commercial strategy.




